Document:

EX-4.16

Exhibit
4.16

RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT

     This Right of First Refusal and Co-Sale Agreement (this “Agreement”), dated as of
April 30, 2009, is made by and among ComVest NationsHealth Holdings, LLC, a Delaware limited
liability company (“Parent”), NationsHealth, Inc., a Delaware corporation (the
“Company”), MHR Capital Partners Master Account, LP, MHR Capital Partners (100) LP, OTQ,
LLC, and Mark H. Rachesky M.D., as a holder of record and as authorized signatory for certain other
entities, (collectively, with their respective Affiliates and any successor to any of the
foregoing, “MHR,” provided, that any representations and covenants made by any of the foregoing
signatories hereto shall be made severally and not jointly), Glenn Parker, Lewis Stone, Timothy
Fairbanks Mark Lama, and RGGPLS, LLC, a Delaware limited liability company, (each, individually, a
“Key Holder” and, collectively, the “Key Holders” and together with MHR and Parent,
individually, a “Stockholder” and, collectively, the “Stockholders”). Certain
defined terms used in this Agreement are defined in Article 7 and capitalized terms used
but not defined herein shall have the meanings ascribed to such terms in the Merger Agreement (as
defined below).

RECITALS

     WHEREAS, concurrently with the execution of this Agreement, Parent, NationsHealth Acquisition
Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and
the Company have entered into that certain Agreement and Plan of Merger (the “Merger
Agreement”);

     WHEREAS, pursuant to the Merger Agreement, Merger Sub will merge with and into the Company
(the “Merger”) and the separate corporate existence of Merger Sub shall thereupon cease,
and the Company shall be the surviving corporation in the Merger (the “Surviving
Corporation”);

     WHEREAS, in connection with the Merger and immediately prior to the Effective Time, each of
the Stockholders shall contribute all issued and outstanding shares of Company Common Stock and
Company Restricted Stock owned, beneficially and of record, by each of them (or their respective
Affiliates) (the “Rollover Shares”) in exchange for the same number of shares of the Merger
Sub Non-Voting Common Stock at a price per share equal to $0.12 (the “Exchange”) in
accordance with the terms and conditions of the Exchange and Rollover Agreement;

     WHEREAS, in connection with the Merger and at the Effective Time, (a) each share of issued and
outstanding Company Common Stock, including shares of Company Restricted Stock (other than shares
to be canceled in accordance with Section 2.1(c) of the Merger Agreement, the Dissenting Shares,
and the shares of Preferred Stock issued at or immediately prior to the Effective Time in
connection with the Preferred Stock Investment and the Preferred Stock Investment Option (if
exercised)) shall be converted into the right to receive from the Surviving Corporation a cash
amount equal to $0.12 per share, (b) each share of Merger Sub Non-Voting Common Stock owned,
beneficially or of record, by each of the Stockholders (or its Affiliates or permitted assigns or
transferees) shall be converted into and become one share of Surviving Corporation Common Stock in
accordance with Section 2.1(a) of the Merger Agreement, and (c)
each share of Merger Sub Voting Common Stock owned, beneficially or of record, by Parent shall
be converted into and become one share of Surviving Corporation Common Stock in accordance with the
terms and conditions of Section 2.1(a) of the Merger Agreement;

 

 

     WHEREAS, concurrently with the execution of this Agreement, the Company and Parent have
entered into the Bridge Loan Documents pursuant to which Parent has agreed to provide the Bridge
Loan which Bridge Loan shall be converted into shares of Preferred Stock at the Effective Time;

     WHEREAS, all of the outstanding obligations under the Bridge Loan may be converted into shares
of Preferred Stock in accordance with the Bridge Loan Documents and/or the Merger Agreement;

     WHEREAS, concurrently with the execution of this Agreement, the Company, Parent, the Key
Holders and MHR have entered into the other Preferred Stock Investment Documents to which each is a
party, including the Series A Preferred Stock Purchase Agreement, dated the date hereof (the
“Series A Stock Purchase Agreement”), by and between Parent and the Company, pursuant to
which Parent shall purchase, and the Company shall sell, shares of Preferred Stock and the Company
shall grant to Parent the Preferred Stock Investment Option;

     WHEREAS, the execution and delivery of this Agreement is a condition to Parent’s purchase of
the Preferred Stock pursuant to the Series A Stock Purchase Agreement, Parent’s execution and
delivery of the Series A Stock Purchase Agreement, and Parent’s funding of the Bridge Loan; and

     WHEREAS, at the Effective Time, each of the Stockholders shall own, beneficially or of record,
in such Stockholder’s name (or in the name(s) of its Affiliates or permitted assigns or
transferees) the number of shares of Surviving Corporation Common Stock and/or Preferred Stock set
forth opposite such Stockholders name on Schedule A attached hereto; and

     WHEREAS, the Company and each of the Stockholders desire to enter into this Agreement for the
purposes, among others, of providing certain rights and restrictions with respect to the Capital
Stock owned by the Stockholders and the Preferred Stock owned by Parent.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,
the parties hereto do hereby mutually covenant and agree as follows:

ARTICLE 1

GENERAL TRANSFER RESTRICTIONS

     1.1 General Stockholder Restrictions. Neither any Key Holder nor MHR may sell, give,
pledge, transfer, encumber, or otherwise dispose of all or any portion of their respective Capital
Stock, whether now owned or acquired subsequent to the date of this Agreement, except as may
otherwise be specifically provided for in this Agreement. This Agreement shall not apply to or
restrict the transfer of the Notes.

2

 

     1.2 Transfer Void; Equitable Relief. Any sale, transfer, offer to sell, pledge,
mortgage, hypothecation, encumbrance, alienation or disposition of any Key Holder’s or MHR’s
Capital Stock not made in compliance with the requirements of this Agreement shall be null and void
ab initio, shall not be recorded on the books of the Company or its transfer agent and shall not be
recognized by the Company. Each party hereto acknowledges and agrees that any breach of this
Agreement would result in substantial harm to the other parties hereto for which monetary damages
alone could not adequately compensate. Therefore, the parties hereto unconditionally and
irrevocably agree that any non-breaching party hereto shall be entitled to seek protective orders,
injunctive relief and other remedies available at law or in equity (including, without limitation,
seeking specific performance or the rescission of purchases, sales and other transfers of Capital
Stock not made in strict compliance with this Agreement).

     1.3 Key Holder Restrictions. In addition to the other restrictions set forth in this
Agreement, except for sales or transfers pursuant to Article 4 or Article 5, no Key
Holder may sell, give, pledge, transfer, encumber, or otherwise dispose of all or any portion of
the Key Holder’s Capital Stock unless (i) the per share purchase price received by such Key Holder
for the Capital Stock is equal to or greater than $0.30 (appropriately adjusted to reflect any
stock dividend, split, combination or other recapitalization affecting the Capital Stock occurring
after the Effective Time), (ii) such Key Holder or its permitted transferee(s) set forth in
Section 1.5 has been the record owner of such Capital Stock for at least fifty-four (54)
months commencing at the Effective Time, (iii) such Key Holder complies with Article 2, and
(iv) such Key Holder receives written notice from the Company stating that the Company’s Board of
Directors has determined in good faith that the transferee(s) of such Key Holder’s Capital Stock
does not directly or indirectly compete with the Company.

     1.4 MHR Restrictions. In addition to the other restrictions set forth in this
Agreement, except for sales or transfers pursuant to Article 4 or Article 5, MHR
shall not sell, give, pledge, transfer, encumber, or otherwise dispose of all or any portion of
MHR’s Capital Stock unless (i) the per share purchase price received by MHR for the Capital Stock
is equal to or greater than $0.30 (appropriately adjusted to reflect any stock dividend, split,
combination or other recapitalization affecting the Capital Stock occurring after the Effective
Time), (ii) MHR or its permitted transferee(s) set forth in Section 1.6 has been the record
owner of such Capital Stock for at least thirty (30) months commencing at the Effective Time, (iii)
MHR complies with Article 3, and (iv) MHR receives written notice from the Company stating
that the Company’s Board of Directors has determined in good faith that the transferee(s) of MHR’s
Capital Stock does not directly or indirectly compete with the Company.

3

 

     1.5 Key Holder Exempt Transfers. The provisions of Section 1.3 and
Article 2 shall not apply (a) in the case of a Key Holder that is a natural person, upon a
transfer of such Key Holder’s Capital Stock made for bona fide estate planning purposes, either
during his or her lifetime or on his or her death by will or intestacy to his or her spouse, child
(natural or adopted), or any other direct lineal descendant of such Key Holder (or his or her
spouse) (all of the foregoing collectively referred to as “family members”), or any other person
approved by the Company’s Board of Directors, or any custodian or trustee of any trust, partnership
or limited liability company for the benefit of, or the ownership interests of which are owned
wholly by, such Key Holder or any such family members, (b) in the case of a Key Holder that is an
entity, upon a transfer by such Key Holder to its stockholders, members, partners or other equity
holders, (c) to a repurchase of such Key Holder’s Capital Stock by the Company at a price no
greater than that originally paid by such Key Holder for such Capital Stock approved by the
Company’s Board of Directors, and (d) to a pledge of such Key Holder’s Capital Stock that was
granted before the date of this Agreement, was disclosed to Parent, and creates a mere security
interest in the pledged Capital Stock so long s such pledgee thereof agrees in writing in advance
to be bound by and comply with all applicable provisions of this Agreement to the same extent as if
it were the Key Holder making such pledge; provided that in each case set forth in clauses
(a), (b), (c), and (d) above (A) such Key Holder shall deliver prior written notice to Parent of
such pledge, gift or transfer, (B) such shares of Capital Stock shall at all times remain subject
to the terms and restrictions set forth in this Agreement, (C) such transferee shall, as a
condition to such issuance, deliver a counterpart signature page to this Agreement as confirmation
that such transferee shall be bound by all the terms and conditions of this Agreement as a Key
Holder (but only with respect to the securities so transferred to the transferee), including the
obligations of a Key Holder with respect to Article 2, and (D) such Key Holder receives
written notice from the Company stating that the Company’s Board of Directors has determined in
good faith that the transferee(s) of such Key Holder’s Capital Stock does not directly or
indirectly compete with the Company; and provided, further, in the case of any
transfer pursuant to clause (a) or (b) above, that such transfer is made pursuant to a transaction
in which there is no consideration actually paid for such transfer. In the event of a transfer
pursuant to this Section 1.5, such transferee shall (x) assume the holding period of a Key
Holder with respect to calculating the holding period of such Capital Stock set forth in
Section 1.3 and (y) be entitled to all of the rights, benefits and interest that such Key
Holder has under this Agreement.

4

 

     1.6 MHR Exempt Transfers. The provisions of Section 1.4 and Article 3
shall not apply (a) to any transfer by MHR of Capital Stock to any of its Affiliates, stockholders,
members, partners or other equity holders, (b) to a repurchase of MHR’s Capital Stock by the
Company at a price no greater than that originally paid by MHR for such Capital Stock approved by
the Company’s Board of Directors, (c) to a pledge of MHR’s Capital Stock that creates a mere
security interest in the pledged Capital Stock; provided that the pledgee thereof agrees in
writing in advance to be bound by and comply with all applicable provisions of this Agreement to
the same extent as if it were MHR making such pledge, (d) to any transactions in which MHR lends or
borrows any Capital Stock to brokers, banks or other financial institutions for the purpose of
effecting any margin transactions, including any transactions effecting or resulting in any pledge
or other encumbrance (in existence or hereinafter created) over such Capital Stock in the ordinary
course of business without the transferee being bound in writing in advance to comply with
applicable provisions of this Agreement, (e) to a transfer to any investor of such MHR entity that
is an investment fund in connection with a pro rata distribution of shares to all investors at the
time of expiration or termination of the fund, and (f) in the case of any MHR party that is a
natural person, upon a transfer of such person’s Capital Stock made for bona fide estate planning
purposes, either during his or her lifetime or on his or her death by will or intestacy to his or
her spouse, child (natural or adopted), or any other direct lineal descendant of such person (or
his or her spouse) (all of the foregoing collectively referred to as “family members”), or any
other person approved by the Company’s Board of Directors, or any custodian or trustee of any
trust, partnership or limited liability company for the benefit of, or the ownership interests of
which are owned wholly by, such person or any such family members, provided that in each
case set forth in clauses (a), (b), (c), (e) and (f) above (A) MHR shall deliver prior written
notice to Parent of such pledge, gift or transfer, (B) such shares of Capital
Stock shall at all times remain subject to the terms and restrictions set forth in this
Agreement, (C) such transferee shall, as a condition to such issuance, deliver a counterpart
signature page to this Agreement as confirmation that such transferee shall be bound by all the
terms and conditions of this Agreement as a Stockholder (but only with respect to the securities so
transferred to the transferee), including the obligations of a Stockholder with respect to
Article 3, and (D) in the case of a transfer other than to an affiliated fund of MHR that
conducts no business other than holding securities, MHR receives written notice from the Company
stating that the Company’s Board of Directors has determined in good faith that the transferee(s)
of MHR’s Capital Stock does not directly or indirectly compete with the Company; and
provided, further, in the case of any transfer pursuant to clause (a) above, that
such transfer is made pursuant to a transaction in which there is no consideration actually paid
for such transfer. In the event of a transfer pursuant to this Section 1.6, such
transferee shall (x) assume the holding period of MHR with respect to calculating the holding
period of such Capital Stock set forth in Section 1.4 and (y) be entitled to all of the
rights, benefits and interest that MHR has under this Agreement.

     1.7 Exempted Offerings. Notwithstanding the foregoing or anything to the contrary
herein, the provisions of Article 1, Article 2, Article 3, and Article
4 shall not apply to the sale of any Capital Stock (a) to the public in an offering pursuant to
an effective registration statement under the Securities Act of 1933, as amended or (b) pursuant to
a Liquidation Event (as defined in the Company’s Third Amended and Restated Certificate of
Incorporation).

ARTICLE 2

RIGHT OF FIRST REFUSAL AND CO-SALE RIGHTS

     2.1 Right of First Refusal.

          (a) Grant. Subject to the terms of Article 1, each Key Holder hereby
unconditionally and irrevocably grants to the Company a Right of First Refusal to purchase all or
any portion of the Capital Stock that such Key Holder (a “Selling Key Holder”) may propose
to transfer in a Key Holder Proposed Transfer, at the same price and on the same terms and
conditions as those offered by the Key Holder Prospective Transferee.

5

 

          (b) Notice. Each Selling Key Holder proposing to make a Key Holder Proposed Transfer
shall first deliver to the Company and Parent a written notice (a “Key Holder Proposed Transfer
Notice”) not later than forty-five (45) days prior to the consummation of such Key
Holder Proposed Transfer, which shall (i) state the Selling Key Holder’s intention to transfer or
sell Capital Stock to a Key Holder Prospective Transferee, the identity of such Key Holder
Prospective Transferee, the amount and types of Capital Stock proposed to be transferred, the per
share purchase price for such Capital Stock and a summary of the other material terms of the Key
Holder Proposed Transfer (including, without limitation, the proposed transfer date), and (ii)
invite the Company to make an offer to purchase all or a portion of such Capital Stock at the per
share purchase price and on the terms and conditions set forth in the Key Holder Proposed Transfer
Notice. To exercise its Right of First Refusal under this Section 2.1, the Company must
deliver a Company Notice to the Selling Key Holder within fifteen (15) days after delivery of the
Key Holder Proposed Transfer Notice.

          (c) Grant of Secondary Refusal Right to Parent. Subject to the terms of Article
1, each Key Holder hereby unconditionally and irrevocably grants to Parent a Secondary Refusal
Right to purchase all or any portion of the Capital Stock not purchased by the Company pursuant to
the Right of First Refusal, as provided in Section 2.1(a). If the Company does not intend
to exercise its Right of First Refusal with respect to all of the Capital Stock set forth in a Key
Holder Proposed Transfer Notice, the Company must deliver a Secondary Notice to the Selling Key
Holder and to Parent to that effect no later than fifteen (15) days after the Selling Key Holder
delivers the Key Holder Proposed Transfer Notice to the Company. To exercise its Secondary Refusal
Right, Parent must deliver a Parent Notice to the Selling Key Holder and the Company within fifteen
(15) days after the later of (i) the Company’s deadline for its delivery of the Secondary Notice as
provided in this Section 2.1(c), or (ii) the Company’s actual delivery of such Secondary
Notice.

          (d) Consideration; Closing. If the consideration proposed to be paid for the Capital
Stock by the Key Holder Prospective Transferee in the Key Holder Proposed Transfer is in property,
services or other non-cash consideration, the fair market value of the consideration shall be as
determined in good faith by the Company’s Board of Directors and as set forth in the Company Notice
or the Parent Notice. If the Company or Parent cannot for any reason pay for the Capital Stock
proposed to be transferred in the Key Holder Proposed Transfer in the same form of non-cash
consideration, the Company or Parent may pay the cash value equivalent thereof, as determined in
good faith by the Company’s Board of Directors and as set forth in the Company Notice or the Parent
Notice. The closing of the purchase of Capital Stock by the Company and Parent pursuant to this
Section 2.1 shall take place, and all payments from the Company and Parent shall have been
delivered to the Selling Key Holder, by the later of (i) the proposed transfer date specified in
the Key Holder Proposed Transfer Notice, or (ii) sixty (60) days after delivery of the Key Holder
Proposed Transfer Notice.

     2.2 Right of Co-Sale.

          (a) Exercise of Right. If any Capital Stock set forth in a Key Holder Proposed
Transfer Notice is not purchased pursuant to Section 2.1 and thereafter is to be sold to a
Key Holder Prospective Transferee, Parent may elect to exercise the Right of Co-Sale and
participate on a pro rata basis in the Key Holder Proposed Transfer as set forth in Section
2.2(b) below and otherwise on the same terms and conditions specified in the Key Holder
Proposed Transfer Notice (provided that if Parent wishes to sell Preferred Stock, the price set
forth in the Key Holder Proposed Transfer Notice shall be appropriately adjusted based on the
conversion ratio of the Preferred Stock into Common Stock). To exercise the Right of Co-Sale,
Parent must give the Selling Key Holder written notice to that effect within fifteen (15) days
after the deadline for delivery of the Parent Notice set forth in Section 2.1(c), and upon
giving such notice Parent shall be deemed to have effectively exercised the Right of Co-Sale.

6

 

          (b) Shares Includable. If Parent timely exercises the Right of Co-Sale by delivering
the written notice provided for in Section 2.2(a), Parent may include in the Key Holder
Proposed Transfer all or any part of Parent’s Capital Stock equal to the product obtained by
multiplying (i) the aggregate number of shares of Capital Stock subject to the Key Holder Proposed
Transfer (excluding shares purchased by the Company pursuant to the Right of First Refusal or by
Parent pursuant to the Secondary Refusal Right) by (ii) a fraction, the numerator of
which is the number of shares of Capital Stock owned by Parent immediately before consummation
of the Key Holder Proposed Transfer and the denominator of which is the total number of shares of
Capital Stock owned by Parent immediately prior to the consummation of the Key Holder Proposed
Transfer (including any shares that Parent has agreed to purchase pursuant to the Secondary Refusal
Right), plus the number of shares of Capital Stock held by the Selling Key Holder. To the extent
Parent exercises such right of participation in accordance with the terms and conditions set forth
herein, the number of shares of Capital Stock that the Selling Key Holder may sell in the Key
Holder Proposed Transfer shall be correspondingly reduced.

          (c) Delivery of Certificates. Parent shall effect its participation in the Key Holder
Proposed Transfer by delivering to the Selling Key Holder, no later than fifteen (15) days after
Parent’s exercise of the Right of Co-Sale, one or more stock certificates, properly endorsed for
transfer to the Key Holder Prospective Transferee, representing:

               (i) the number of shares of Common Stock that Parent elects to include in the Key Holder
Proposed Transfer; or

               (ii) the number of shares of Preferred Stock that is at such time convertible into the number
of shares of Common Stock that Parent elects to include in the Key Holder Proposed Transfer;
provided, however, that if the Key Holder Prospective Transferee objects to the
delivery of convertible Preferred Stock in lieu of Common Stock, Parent shall first convert the
Preferred Stock into Common Stock and deliver Common Stock as provided above.

          (d) Purchase Agreement. The parties hereby agree that the terms and conditions of any
sale pursuant to this Section 2.2 will be memorialized in, and governed by, a written
purchase and sale agreement with customary terms and provisions for such a transaction and the
parties further covenant and agree to enter into such an agreement as a condition precedent to any
sale or other transfer pursuant to this Section 2.2.

          (e) Deliveries. Each stock certificate Parent delivers to the Selling Key Holder
pursuant to Section 2.2(c) will be transferred to the Key Holder Prospective Transferee
against payment therefor in consummation of the sale of the Capital Stock pursuant to the terms and
conditions specified in the Key Holder Proposed Transfer Notice and the purchase and sale
agreement, and the Selling Key Holder shall concurrently therewith remit to Parent, or direct
payment to Parent of, the portion of the sale proceeds to which Parent is entitled by reason of its
participation in such sale. If any Key Holder Prospective Transferee or Transferees refuse(s) to
purchase securities subject to the Right of Co-Sale from Parent exercising its Right of Co-Sale
hereunder, no Selling Key Holder may sell any Capital Stock to such Key Holder Prospective
Transferee or Transferees unless and until, simultaneously with such sale, such Selling Key Holder
purchases all securities subject to the Right of Co-Sale from Parent on the same terms and
conditions (including the proposed purchase price) as set forth in the Key Holder Proposed Transfer
Notice.

          (f) Additional Compliance. If any Key Holder Proposed Transfer is not consummated
within forty-five (45) days after receipt of the Key Holder Proposed Transfer Notice by the
Company, the Selling Key Holder shall continue to hold its Capital Stock subject
to all of the terms and conditions of this Agreement and may not sell such Capital Stock
without first complying in full with each provision of this Article 2.

7

 

     2.3 Effect of Failure to Comply.

          (a) Violation of First Refusal Right. If any Selling Key Holder becomes obligated to
sell any Capital Stock to the Company or Parent under this Agreement and fails to deliver such
Capital Stock in accordance with the terms of this Agreement, the Company and/or Parent may, at its
option, in addition to all other remedies it may have, send to such Selling Key Holder the purchase
price for such Capital Stock as is herein specified and transfer to the name of the Company or
Parent (or request that the Company effect such transfer in the name of Parent) on the Company’s
books the certificate or certificates representing the Capital Stock to be sold.

          (b) Violation of Co-Sale Right. If any Selling Key Holder purports to sell any
Capital Stock in contravention of the Right of Co-Sale (a “Key Holder Prohibited Transfer”)
and Parent desires to exercise its Right of Co-Sale under Section 2.2, Parent may, in
addition to such remedies as may be available by law, in equity or hereunder, require such Selling
Key Holder to purchase from Parent the type and number of shares of Capital Stock that Parent would
have been entitled to sell to the Key Holder Prospective Transferee under Section 2.2 had
the Key Holder Prohibited Transfer been effected pursuant to and in compliance with the terms of
Section 2.2. The sale will be made on the same terms and subject to the same conditions as
would have applied had the Selling Key Holder not made the Key Holder Prohibited Transfer, except
that the sale (including, without limitation, the delivery of the purchase price) must be made
within ninety (90) days after Parent learns of the Key Holder Prohibited Transfer, as opposed to
the timeframe prescribed in Section 2.2. Such Selling Key Holder shall also reimburse
Parent for any and all reasonable and documented out-of-pocket fees and expenses, including
reasonable legal fees and expenses, incurred in connection with the exercise or the attempted
exercise of Parent’s rights under Section 2.2.

ARTICLE 3

RIGHT OF FIRST OFFER

     3.1 Right of First Offer.

          (a) Right of First Offer. Subject to the terms of Article 1 and this
Section 3.1, if at any time MHR desires to sell, offer to sell, pledge, mortgage,
hypothecate, encumber, alienate or dispose of any of its Capital Stock, MHR shall promptly give
Parent written notice thereof (the “Offer Notice”). The Offer Notice shall include a
description of the type of, and the number of shares of, Capital Stock that MHR desires to sell or
transfer (the “Offered Shares”), the purchase price for the Offered Shares, and other
material terms and conditions for the sale or transfer of the Offered Shares. Parent shall have
the right, but not the obligation, on an exclusive basis, for a period of thirty (30) days after
receipt of the Offer Notice, to purchase the Offered Shares at the price and on the terms set forth
in the Offer Notice. Parent shall be entitled to apportion the Offered Shares to be purchased
pursuant to this Section 3.1(a) among its Affiliates, provided that Parent notifies MHR of
such allocation.

8

 

          (b) Non-Exercise of Right of First Offer. To the extent that Parent does not exercise
its Right of First Offer, MHR shall have a period of ninety (90) days from the expiration of the
Right of First Offer in which to sell the Offered Shares to a third-party transferee(s), at a price
not less than and on material terms no more favorable to the offeree than those set forth in the
Offer Notice. In the event that MHR does not sell the Offered Shares within such ninety (90) day
period, Parent’s Right of First Offer shall continue to be applicable to any subsequent disposition
of the Offered Shares by MHR until such rights lapse in accordance with the terms of this
Agreement. Furthermore, the exercise or non-exercise of the rights of Parent under this
Section 3.1 shall not adversely affect its rights to make subsequent purchases from MHR of
Offered Shares.

          (c) Cooperation. At MHR’s reasonable request and at MHR’s expense, the Company shall
cooperate with, and provide assistance to, MHR in connection with any sale of Offered Shares under
this Section 3.1 (including, without limitation, providing information to a proposed
transferee in such transfer); provided that (i) such cooperation and assistance complies
with the Company’s Third Amended and Restated Certificate of Incorporation, the Company’s Amended
and Restated Bylaws, and all applicable Laws, and includes providing new share certificates to
reflect such transfer and legal opinions reasonably requested and agreeing to provide the
transferee of such Offered Shares with audited annual financial statements of the Company and
monthly unaudited financial statements of the Company promptly as reasonably practicable following
such financial statements becoming available; provided that such transferee executes and
delivers to the Company a confidentiality and non-disclosure agreement in form and substance
reasonably acceptable to the Company’s Board of Directors, provided that the Company shall not have
any obligations to provide financial statements to more than ten (10) such transferees, (ii) the
Company is not required to provide to any such transferee any information which the Company, in its
sole and absolute discretion, determines would be materially detrimental to the Company if provided
or would result in a breach of any confidentiality agreement if provided or would cause a
disclosure of non-public information if provided, and (iii) prior to the Company providing any
assistance or information under this Section 3.1(c), MHR and any proposed transferee must
execute and deliver to the Company a confidentiality and non-disclosure agreement in form and
substance reasonably acceptable to the Company’s Board of Directors.

ARTICLE 4

TAG ALONG RIGHTS

     4.1 Tag-Along Rights.

          (a) Exercise of Right. Subject to the terms of Section 4.3 below, in the
event that Parent (or any of its Affiliates that hold any shares of Capital Stock) proposes to make
a Parent Proposed Transfer, Parent must deliver a Parent Proposed Transfer Notice to the
Stockholders (other than Parent) not later than forty-five (45) days prior to the consummation of
such Parent Proposed Transfer, which notice shall (i) state Parent’s intention to transfer or sell
Capital Stock to a Parent Prospective Transferee, the identity of such Parent Prospective
Transferee, the amount and types of Capital Stock proposed to be transferred, the per share
purchase price (which shall be reflected on an as converted to Common Stock basis) for such Capital
Stock and a summary of the other material terms of the Parent Proposed Transfer

9

 

(including, without limitation, the proposed transfer date) and (ii) invite the Stockholders
to participate in the Parent Proposed Transfer at the same per share purchase price (which shall be
reflected on an as converted to Common Stock basis) and in the form of consideration and on the
terms and conditions set forth in the Parent Proposed Transfer Notice. In order for a Stockholder
(other than Parent) to exercise its Tag-Along Rights and participate on a pro rata basis in the
Parent Proposed Transfer, such Stockholder must deliver a Stockholder Notice to Parent within
fifteen (15) days after delivery of the Parent Proposed Transfer Notice, and, upon giving such
Stockholder Notice, the Stockholder shall be deemed to have effectively exercised the Tag-Along
Right.

          (b) Shares Includable. If such Stockholder timely exercises the Stockholder’s
Tag-Along Right by delivering the Stockholder Notice provided for in Section 4.1(a), such
Stockholder may include in the Parent Proposed Transfer all or any part of such Stockholder’s
Capital Stock equal to the product obtained by multiplying (i) the aggregate number of shares of
Capital Stock (on an as converted to Common Stock basis) subject to the Parent Proposed Transfer by
(ii) a fraction, the numerator of which is the number of shares of Capital Stock (determined on a
fully diluted and as converted to Common Stock basis assuming full conversion or exercise of all of
the Company’s convertible securities and Options, other than the Notes) owned by such Stockholder,
and the denominator of which is the total number of shares of Capital Stock (determined on a fully
diluted and as converted to Common Stock basis assuming full conversion or exercise of all of the
Company’s convertible securities and Options, other than the Notes) owned (immediately prior to the
consummation of the Parent Proposed Transfer), in the aggregate, by all of such Stockholders,
including Parent, and other persons who have tag-along rights. To the extent such Stockholder
exercises such right of participation in accordance with the terms and conditions set forth herein,
the number of shares of Capital Stock that Parent may sell in the Parent Proposed Transfer shall be
correspondingly reduced.

          (c) Delivery of Certificates. Such Stockholder shall effect its participation in the
Parent Proposed Transfer by delivering to Parent, no later than fifteen (15) days after the
Stockholder’s exercise of the Tag-Along Right, one or more stock certificates, properly endorsed
for transfer to the Parent Prospective Transferee, representing:

               (i) the number of shares of Common Stock that such Stockholder elects to include in the Parent
Proposed Transfer; or

               (ii) the number of shares of Preferred Stock that are at such time convertible into the number
of shares of Common Stock that the Stockholder elects to include in the Parent Proposed Transfer;
provided, however, that if the Parent Prospective Transferee objects to the
delivery of convertible Preferred Stock in lieu of Common Stock, the Stockholder shall first
convert the Preferred Stock into Common Stock and deliver Common Stock as provided above.

10

 

          (d) Purchase Agreement. The parties hereby agree that the terms and conditions of any
sale pursuant to this Section 4.1 will be memorialized in, and governed by, a written
purchase and sale agreement with customary terms and provisions for such a transaction and the
parties further covenant and agree to enter into such an agreement as a condition precedent to any
sale or other transfer pursuant to this Section 4.1, which agreement shall be on
terms and conditions no less favorable to the selling Stockholders, than the terms and
conditions found in Parent’s agreement; provided, that such selling Stockholders (i) shall
be required to make representations and warranties solely with respect (A) such Stockholder’s due
organization, power and authority, (B) such Stockholder’s ownership of the shares of Capital Stock
and ability to freely convey such shares of Capital Stock without liens or encumbrances, (C) such
Stockholder’s non-contravention of its charter, bylaws or other organizational documents or
material agreements, and (D) the enforceable nature of such Stockholder’s obligations thereunder
(collectively, the “Stockholder Representations”), (ii) shall indemnify the Parent
Prospective Transferee in connection with a Tag-Along with respect to breaches of the Stockholder
Representations, in am amount not to exceed the full amount of the consideration received by such
selling Stockholder, and (iii) shall not be required to participate in any escrow relating to such
Tag-Along Right.

          (e) Deliveries. Each stock certificate a Stockholder delivers to the Parent
Prospective Transferee pursuant to Section 4.1(c) will be transferred to the Parent
Prospective Transferee against payment therefor in consummation of the sale of the Capital Stock
pursuant to the terms and conditions specified in the Parent Proposed Transfer Notice and the
corresponding purchase and sale agreement, and the Parent Prospective Transferee shall concurrently
therewith remit or direct payment to such Stockholder of the portion of the sale proceeds to which
such Stockholder is entitled by reason of its participation in such sale. If any Parent
Prospective Transferee refuses to purchase securities subject to the Tag-Along Right from the
Stockholder exercising its Tag-Along Right hereunder, Parent may not sell any Capital Stock to such
Parent Prospective Transferee unless and until, simultaneously with such sale, Parent purchases all
securities subject to the Tag-Along Right from the Stockholder on the same terms and conditions
(including the proposed purchase price (which shall be reflected on an as converted to Common Stock
basis)) as set forth in Parent Proposed Transfer Notice.

          (f) Additional Compliance. If any Parent Proposed Transfer is not consummated within
sixty (60) days after receipt of the Parent Proposed Transfer Notice by the Stockholders, Parent
shall continue to hold its Capital Stock subject to all of the terms and conditions of this
Agreement and may not sell such Capital Stock without again first complying in full with each
provision of this Article 4.

     4.2 Effect of Failure to Comply. If Parent purports to sell any Capital Stock in
contravention of the Tag-Along Right (a “Parent Prohibited Transfer”) and a Stockholder
desires to exercise its Tag-Along Right under Section 4.1, the Stockholder may, in addition
to such remedies as may be available by law, in equity or hereunder, require Parent to purchase
from the Stockholder the type and number of shares of Capital Stock that the Stockholder would have
been entitled to sell to the Parent Prospective Transferee under Section 4.1 had Parent
Prohibited Transfer been effected pursuant to and in compliance with the terms of Section
4.1. The sale will be made on the same terms and subject to the same conditions as would have
applied had Parent not made the Parent Prohibited Transfer, except that the sale (including,
without limitation, the delivery of the purchase price (which shall be reflected on an as converted
to Common Stock basis)) must be made within ninety (90) days after the Stockholder learns of the
Parent Prohibited Transfer, as opposed to the timeframe prescribed in Section 4.1. Parent
shall also reimburse the Stockholder for any and all reasonable and documented out-of-pocket fees
and expenses, including reasonable legal fees and expenses, incurred in connection with the
exercise or the attempted exercise of the Stockholder’s rights under Section 4.1.

11

 

     4.3 Exempt Transfers. Notwithstanding the foregoing, the Tag-Along Right shall not
apply to any Parent Proposed Transfer of Capital Stock by Parent to any of its Affiliates;
provided that, upon any such transferee ceasing to be an Affiliate of Parent, Parent shall
be required to comply with Section 4.1 at such time.

     4.4
No Other Restrictions. Other than the restrictions contained
in this Agreement and restrictions imposed by Law, Parent may assign,
sell, offer to sell, pledge, mortgage, hypothecate, encumber,
alienate or dispose of any Capital Stock (or any interest therein) owned by Parent.

ARTICLE
5
 DRAG ALONG RIGHTS

     5.1 Drag Along Rights.

          (a) In the event of an Approved Drag-Along Sale, the Company shall deliver twenty (20) days’
prior written notice thereof to each Stockholder and the other Persons that become a party to this
Agreement, which notice shall specify (i) that the Company desires to cause the Stockholders and
the other Persons that become a party to this Agreement, to participate in such transaction on the
same terms and conditions as available to all of the holder of Share Equivalents, (ii) the
consideration, if any, to be received by the Company, the Stockholders and the other Persons that
become a party to this Agreement, (iii) any material terms and conditions of the Approved
Drag-Along Sale, (iv) the identity of the other Person or Persons party to the Approved Drag-Along
Sale, (v) the anticipated closing date of the Approved Drag-Along Sale, and (vi) the action or
actions required of each Stockholder and the other Persons that become a party to this Agreement in
order to complete or facilitate such Approved Drag-Along Sale.

          (b) Each Stockholder and the other Persons that become a party to this Agreement shall (i)
sell their respective Share Equivalents in connection with such Approved Drag-Along Sale and (ii)
vote for, consent to and raise no objections to, shall not bring a claim against and shall not
contest such Approved Drag-Along Sale. If the Approved Drag-Along
Sale is structured as (x) a merger or consolidation, each Stockholder and the other Persons that become a party to this
Agreement shall waive any dissenters rights, appraisal rights or similar rights in connection with
such merger or consolidation; or (y) a sale of stock or a tax free contribution of stock, each
Stockholder and the other Persons that become a party to this Agreement shall (A) agree to sell or
contribute all of their Share Equivalents and rights to acquire Share Equivalents on the terms and
conditions approved by the Company’s Board of Directors and the holders of a majority of the
Capital Stock then outstanding and (B) execute such purchase agreement or contribution agreement
and such other documents as executed by the holders of a majority of the Capital Stock containing
terms and conditions no less favorable to the selling Stockholders and the other Persons that
become a party to this Agreement than the terms and conditions applicable to the holders of a
majority of the Capital Stock, including making the same representations, warranties, covenants,
indemnities and agreements as the holders of a majority of the Capital Stock agree to make in
connection with the Approved Drag-Along Sale; provided, that such selling Stockholders (i)
shall only be required to make the
Stockholder Representations, (ii) shall indemnify the prospective purchaser in connection with
an Approved Drag-Along Sale with respect to breaches of the Stockholder Representations, in an
amount not to exceed the full amount of the consideration received by such selling Stockholder,
(iii) shall not be responsible for more than such Stockholder’s pro rata share of reasonable fees,
costs and expenses incurred in connection with any Approved Drag-Along Sale to the extent such
fees, costs and expenses are for the benefit of the Stockholders and are not otherwise paid by the
Company or the prospective purchaser, and (iv) shall not be required to participate in any escrow
relating to such Approve Drag-Along Sale. Each Stockholder, including Parent, and the other
Persons that become a party to this Agreement shall take such other necessary or desirable actions
in connection with the consummation of the Approved Drag-Along Sale as reasonably requested by the
Company.

12

 

          (c) The obligations of the Stockholders and the other Persons that become a party to this
Agreement with respect to the Approved Drag-Along Sale are subject to the satisfaction of the
following conditions: (i) upon the consummation of the Approved Drag-Along Sale, each holder of
Share Equivalents shall receive for such Share Equivalent the same form of consideration and the
same amount of consideration as the holders of a majority of the Share Equivalents receive for each
of their Share Equivalents; (ii) if any holders of a class or series of Capital Stock are given an
option as to the form and amount of consideration to be received, each holder of any class or
series of Capital Stock shall be given the same option; and (iii) each holder of then currently
exercisable rights to acquire shares of a class of Capital Stock shall be given an opportunity to
either (A) exercise such rights prior to the consummation of the Approved Drag-Along Sale or (B)
receive in exchange for such rights consideration equal to the amount determined by multiplying (1)
the same amount of consideration per share of a class or series of Capital Stock received by
holders of such class or series of Capital Stock in connection with the Approved Drag-Along Sale
less the exercise price per share of such class or series of Capital Stock by (2) the number of
shares of such class or series of Capital Stock represented by such rights.

ARTICLE 6

MISCELLANEOUS

     6.1 Term. This Agreement shall automatically terminate upon the earlier of (a) the
consummation of an Approved Drag-Along Sale, (b) the termination of the Merger Agreement in
accordance with its terms, (c) immediately prior to the consummation of the Company’s initial
public offering of its securities or (d) the date the parties hereto consent in writing to the
termination of this Agreement.

     6.2 Effective Date. The effectiveness of this Agreement is conditioned upon the
occurrence of the Effective Time pursuant to the Merger Agreement in effect as of the date hereof
and in the event the Merger Agreement is terminated in accordance with its terms, this Agreement
shall be null and void and have no force or effect.

13

 

     6.3 Legend. Each certificate representing shares of Capital Stock now or hereafter
owned by the Stockholders or issued to any person in connection with a transfer pursuant to this
Agreement shall be endorsed with the following legend:

“THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED
BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN
RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT BY AND AMONG THE STOCKHOLDER,
THE COMPANY AND CERTAIN HOLDERS OF STOCK OF THE COMPANY. COPIES OF SUCH
AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE
COMPANY.”

     The parties hereto agree that the Company may instruct its transfer agent to impose transfer
restrictions on the shares represented by certificates bearing the legend referred to above to
enforce the provisions of this Agreement and the Company agrees to promptly do so. The legend
shall be removed at the request of any holder of Capital Stock following termination of this
Agreement.

     6.4 Notices. All notices, requests and other communications to any party hereunder
shall be in writing and shall be deemed given if delivered personally, sent by facsimile (which is
confirmed by an acknowledgement or transmission report generated by the machine from which the
facsimile was sent indicating that the facsimile was sent in its entirety to the addressee’s
facsimile number) or sent by overnight courier (providing proof of delivery) to the parties at the
following addresses:

			
	               	 	If to Parent, to:

ComVest Investment Partners III, L.P.

One North Clematis

Suite 300

West Palm Beach, Florida 33401

Attention: Cecilio Rodriguez

Facsimile: (561) 671-3225

with a copy (which shall not constitute notice) to:

Foley & Lardner LLP

100 North Tampa Street

Suite 2700

Tampa, FL 33602

Attention: Steven W. Vazquez

Facsimile: (813) 221-4217

If to the Company, to:

NationsHealth, Inc.

13630 NW 8th Street

Suite 210

Sunrise, Florida 33325

Attention: Chief Executive Officer

Facsimile: (954) 903-5005

14

 

			
	               	 	with a copy (which shall not constitute notice) to:

McDermott Will & Emery LLP

201 South Biscayne Boulevard

22nd Floor

Miami, Florida 33131

Phone: 305.358.3500

Fax: 305.347.6500

Attention: Ira J. Coleman, Esq.

               Frederic L. Levenson, Esq.

               Harris Siskind, Esq.

If to the Key Holders, to:

Glenn Parker

530 Carrotwood Terrace

Plantation, Florida 33324

and

Timothy Fairbanks

6605 NW 122nd Avenue

Parkland, Florida 33076

and

Lewis Stone

6618 NW 103rd Lane

Parkland, Florida 33076

and

Mark Lama

225 Potter Road

West Palm Beach, Florida 33405

and

RGGPLS, LLC

13630 NW 8th Street

Suite 210

Sunrise, Florida 33325

15

 

			
	               	 	If to MHR, to:

c/o MHR Fund Management LLC

40 West 57th Street, 24th Floor

New York, NY 10019

Attn: Hal Goldstein

               Emily Fine

               Janet Yeung

Telephone: (212) 262-0005

Facsimile: (212) 262-9356

with a copy (which shall not constitute notice) to:

O’Melveny & Myers LLP

Times Square Tower

7 Times Square

New York, New York 10036

Attention: Doron Lipshitz, Esq.

               Patricia Perez, Esq.

Telephone: (212) 326-2000

Facsimile: (212) 326-2061

or such other address or facsimile number as such party may hereafter specify by like notice to the
other parties hereto. All such notices, requests and other communications shall be deemed received
on the date of receipt by the recipient thereof if received prior to 5 P.M. in the place of receipt
and such day is a Business Day in the place of receipt. Otherwise, any such notice, request or
communication shall be deemed not to have been received until the next succeeding Business Day in
the place of receipt. In the event that an addressee of a notice or communication rejects or
otherwise refuses to accept a notice or other communication delivered or sent in accordance with
this Section 6.4, or if the notice or other communication cannot be delivered because of a
change in address for which no notice was given, then such notice or other communication is deemed
to have been received upon such rejection, refusal or inability to deliver.

     6.5 Amendments; Waivers. Any amendment or modification of or to any provision of this
Agreement, and any consent to any departure of any party from the terms of any provision of this
Agreement, shall be effective only if it is made or given in writing and signed by each party.
Notwithstanding the foregoing sentence, any failure of any of the parties to comply with any
obligation, covenant, agreement or condition herein may be waived by any party entitled to the
benefits thereof only by a written instrument signed by such party granting such waiver, but such
waiver or failure to insist upon strict compliance with such obligation, covenant, agreement or
condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or other
failure. The failure of any party to assert any of its rights under this Agreement or otherwise
shall not constitute a waiver of those rights.

16

 

     6.6 Counterparts and Fax Signatures. This Agreement may be executed in two or more
counterparts (including by means of facsimile or electronically transmitted portable
document format (PDF) signature pages), each of which shall be deemed to be an original, but
all of which together shall constitute and be one and the same instrument; provided, that
fax or electronically transmitted signatures of this Agreement shall be deemed to be originals.
Counterpart signatures need not be on the same page and shall be deemed effective upon receipt.

     6.7 Stock Split. All references to numbers of shares in this Agreement shall be
appropriately adjusted to reflect any stock dividend, split, combination or other recapitalization
affecting the Capital Stock occurring after the Effective Time.

     6.8 Ownership. Except as set forth in Schedule 6.8, each Stockholder
represents and warrants that such Stockholder is the sole legal and beneficial owner of the shares
of Capital Stock subject to this Agreement and that no other person or entity has any interest in
such shares (other than a community property interest as to which the holder thereof has
acknowledged and agreed in writing to the restrictions and obligations hereunder).

     6.9 Headings and Sections. All headings set forth in this Agreement are intended for
convenience only and shall not control or affect the meaning, construction or effect of this
Agreement or of any of its provisions. All references in this Agreement to an article or section
shall mean an article or section of this Agreement (unless otherwise indicated).

     6.10 Entire Agreement. This Agreement (including the exhibits and schedules hereto
and any other documents and instruments referred to herein or contemplated hereby), constitute the
entire agreement, and supersede all other prior agreements and understandings, both written and
oral, among the parties, or any of them, with respect to the subject matter hereof and thereof
(including that certain Letter of Intent).

     6.11 No Third Party Beneficiary. Nothing expressed or implied in this Agreement is
intended, or shall be construed, to confer upon or give any person other than the parties hereto
and their respective heirs, personal representatives, legal representatives, successors and
assigns, any rights or remedies under or by reason of this Agreement, except as expressly provided
in this Agreement.

     6.12 Severability. If any term or other provision of this Agreement is determined by
a non-appealable court of competent jurisdiction to be invalid, illegal or incapable of being
enforced by any rule of law or public policy, all other terms, provisions and conditions of this
Agreement shall nevertheless remain in full force and effect. Upon such determination that any
term or other provision is invalid, illegal or incapable of being enforced, the parties hereto
shall negotiate in good faith to modify this Agreement so as to effect the original intent of the
parties as closely as possible to the fullest extent permitted by applicable law in an acceptable
manner to the end that the transactions contemplated hereby are fulfilled to the extent possible.

     6.13 Schedules, Exhibits. All exhibits or schedules attached to this Agreement shall
be deemed part of this Agreement and incorporated into this Agreement, as if fully contained in it.
All references in this Agreement to this Agreement shall include all of the exhibits or schedules
attached to this Agreement.

     6.14 Governing Law; Jurisdiction. 

17

 

          (a) The laws of the State of Delaware (without giving effect to its conflicts of law
principles) govern this Agreement and all matters arising out of or relating to this Agreement and
any of the transactions contemplated hereby, including its negotiation, execution, validity,
interpretation, construction, performance and enforcement.

          (b) The parties hereto hereby irrevocably submit to the federal and state courts located in
the State of Delaware over any action or proceeding arising out of or relating to this Agreement or
any of the transactions contemplated hereby and each party hereto hereby irrevocably agrees that
all claims in respect of such action or proceeding may be heard and determined in such courts. The
parties hereto hereby irrevocably waive any objection which they may now or hereafter have to the
laying of venue of any action or proceeding brought in such court or any claim that such action or
proceeding brought in such court has been brought in an inconvenient forum. Each of the parties
hereto agrees that a judgment in such action or proceeding may be enforced in other jurisdictions
by suit on the judgment or in any other manner provided by Law. Each of the parties hereto hereby
irrevocably consents to process being served by any party to this Agreement in any action or
proceeding by delivery of a copy thereof in accordance with the provisions of Section 6.4.

     6.15 Further Assurances. Each Stockholder, the Company, and Parent, at the closing of
the transactions contemplated hereby, or at any time or times thereafter, upon request of any party
hereto, will execute such additional instruments, documents or certificates as either party deems
reasonably necessary and to take all such further action in order to effect the transactions
contemplated hereby.

     6.16 Efforts. Each party hereto hereby agrees to take, or cause to be taken, all
commercially reasonable actions, and do, or cause to be done, and to assist and cooperate with the
other party hereto in doing all commercially reasonable things necessary, proper or advisable under
applicable Laws, to consummate and make effective the other transactions contemplated hereunder.

     6.17 Successors and Assigns. This Agreement shall apply to, be binding in all
respects upon and inure to the benefit of the parties and their respective successors and permitted
assigns. No party may assign any of its rights under this Agreement without the prior written
consent of each of the other parties or except as permitted in compliance with the terms and
conditions set forth herein.

     6.18 Transfer or Assignment of Shares. 

          (a) In the event that MHR transfers or assigns in one or a series of transactions at least
fifty percent (50%) of the number of shares of the Capital Stock or any equity or debt securities
convertible, exercisable or exchangeable into shares of the Capital Stock (determined on a fully
diluted and as converted to Common Stock basis assuming full conversion or exercise of all of the
Company’s convertible securities and Options, other than the Notes) owned by MHR at the Effective
Time in compliance with the terms and conditions hereof, any and all of MHR’s rights under
Article 4 may, at the option of MHR be transferred or assigned to the applicable
transferee; provided that such transferee or assignee agrees in writing to be bound by and subject
to the applicable terms and conditions of this Agreement.

18

 

          (b) In the event that Glenn Parker transfers or assigns in one or a series of transactions at
least fifty percent (50%) of the number of shares of the Capital Stock or any equity or debt
securities convertible, exercisable or exchangeable into shares of the Capital Stock (determined on
a fully diluted and as converted to Common Stock basis assuming full conversion or exercise of all
of the Company’s convertible securities and Options, other than the Notes) owned by Glenn Parker at
the Effective Time in compliance with the terms and conditions hereof, any and all of Glenn
Parker’s rights under Article 4 may, at the option of Glenn Parker be transferred or
assigned to the applicable transferee; provided that such transferee or assignee agrees in writing
to be bound by and subject to the applicable terms and conditions of this Agreement.

     6.19 Transaction Costs. Except as set forth in the Merger Agreement and in Sections
2.3(b) and 4.2 hereof, each party hereto shall pay its own fees, costs and expenses incurred in
connection herewith and the transactions contemplated hereby, including the fees, costs and
expenses of its financial advisors, accountants and counsel.

     6.20 Joint Negotiation and Drafting. The parties hereto have participated jointly in
the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent
or interpretation arises, this Agreement shall be construed as jointly drafted by the parties
hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any provision of this Agreement.

ARTICLE 7

CERTAIN DEFINITIONS

     7.1 “Affiliate” means, as to any Person, any other Person that, directly or
indirectly, controls, or is controlled by, or is under common control with, such Person. For this
purpose, “control” (including, with its correlative meanings, “controlled by” and “under common
control with”) shall mean the possession, directly or indirectly, of the power to direct or cause
the direction of management or policies of a Person, whether through the ownership of securities or
partnership or other ownership interests, by contract or otherwise.

     7.2 “Approved Drag-Along Sale” means a Sale of the Company approved by the Board of
Directors of the Company and the holders of a majority of the Capital Stock.

     7.3 “Capital Stock” means (a) shares of Common Stock and Preferred Stock (whether now
outstanding or hereafter issued in any context), (b) shares of Common Stock issued or issuable upon
conversion of Preferred Stock, and (c) shares of Common Stock or Preferred Stock issued or issuable
upon exercise or conversion, as applicable, of stock options, warrants or other convertible
securities of the Company, in each case now owned or subsequently acquired by a Key Holder, MHR, or
Parent, or their respective successors or permitted transferees or assigns. For purposes of
determining the number of shares of Capital Stock held by a Key Holder, MHR, or Parent (or any
other calculation based thereon), all shares of Preferred Stock shall be deemed to have been
converted into Common Stock at the then applicable conversion ratio.

19

 

     7.4 “Company Notice” means written notice from the Company notifying the Selling Key
Holder that the Company intends to exercise its Right of First Refusal as to some or all of the
Capital Stock with respect to any Key Holder Proposed Transfer.

     7.5 “Key Holder Proposed Transfer” means a proposed assignment, sale, pledge,
mortgage, hypothecation, encumbrance, alienation or disposition of or any other similar transfer or
encumbrance of any Capital Stock (or any interest therein) held or owned, beneficially or of
record, by Key Holder pursuant to the terms of a bona fide written offer from a Key Holder
Prospective Transferee.

     7.6 “Key Holder Prospective Transferee” means any third party, who is not an Affiliate
of Key Holder, and who has made a bona fide written offer to purchase any Capital Stock held or
owned, beneficially or of record, by a Key Holder.

     7.7 “Notes” means the (a) Second Amended and Restated 7 3/4% Convertible Secured Note
issued by NationsHealth, Inc., NationsHealth Holdings, L.L.C., United States Pharmaceutical Group,
L.L.C., Diabetes Care & Education, Inc., and National Pharmaceuticals and Medical Products (USA),
LLC in favor of OTQ LLC, dated as of the Effective Time; (b) Second Amended and Restated 7 3/4%
Convertible Secured Note issued by NationsHealth, Inc., NationsHealth Holdings, L.L.C., United
States Pharmaceutical Group, L.L.C., Diabetes Care & Education, Inc., and National Pharmaceuticals
and Medical Products (USA), LLC in favor of MHR Capital Partners Master Account LP, dated as of
the Effective Time; and (c) Second Amended and Restated 7 3/4% Convertible Secured Note issued by
NationsHealth, Inc., NationsHealth Holdings, L.L.C., United States Pharmaceutical Group, L.L.C.,
Diabetes Care & Education, Inc., and National Pharmaceuticals and Medical Products (USA), LLC in
favor of MHR Capital Partners (100) LP, dated as of the Effective Time, as each may be amended,
modified, replaced or refinanced from time to time.

     7.8 “Person” means an individual, a corporation, a limited liability company, a
partnership, an association, a trust or any other entity.

     7.9 “Parent Notice” means written notice from Parent notifying the Company and the
Selling Key Holder that Parent intends to exercise its Secondary Refusal Right as to all or a
portion of the Capital Stock available to Parent with respect to any Key Holder Proposed Transfer.

     7.10 “Parent Proposed Transfer” means any proposed assignment, sale, offer to sell,
pledge, mortgage, hypothecation, encumbrance, alienation or disposition of or any similar transfer
or encumbrance, directly or indirectly, of any Capital Stock (or any interest therein), including
without limitation, the offer, sale, conveyance or other transfer or disposition of any capital
stock or other ownership interests in Parent or any of its Affiliates directly or indirectly
holding Capital Stock.

     7.11 “Parent Proposed Transfer Notice” means written notice from Parent setting forth
the terms and conditions of a Parent Proposed Transfer.

     7.12 “Parent Prospective Transferee” means any person to whom Parent proposes to make
a Parent Proposed Transfer.

20

 

     7.13 “Right of Co-Sale” means the right, but not the obligation, of Parent to
participate in a Key Holder Proposed Transfer on the terms and conditions specified in the Key
Holder Proposed Transfer Notice.

     7.14 Right of First Offer” means the right, but not the obligation, of Parent to
purchase the Offered Shares at the price and on the terms set forth in the Offer Notice.

     7.15 “Right of First Refusal” means the right, but not the obligation, of the Company,
or its permitted transferees or assigns, to purchase some or all of the Capital Stock proposed to
be sold or transferred in a Key Holder Proposed Transfer, at the price and on the terms and
conditions specified in the Key Holder Proposed Transfer Notice.

     7.16 “Sale of the Company” means the sale of the Company to an independent third party
or group of independent third parties pursuant to which such party or parties acquire (a) Capital
Stock of the Company possessing the voting power under normal circumstances to elect a majority of
the Company’s Board of Directors (whether by merger, consolidation or sale or transfer of the
Capital Stock) or (b) all or substantially all of the Company’s assets determined on a consolidated
basis. For purposes of this definition, “independent third party” means any Person who,
immediately prior to such contemplated transaction, (w) does not own or have any voting or economic
rights with respect to more than five percent (5%) of the Capital Stock on a fully-diluted and as
converted to Common Stock basis, (x) is not an Affiliate of any Person who owns or has any voting
or economic right with respect to more than five percent (5%) of the Capital Stock on a
fully-diluted and as converted to Common Stock basis, (y) is not Parent, and (z) is not an
Affiliate of Parent.

     7.17 “Secondary Notice” means written notice from the Company notifying Parent and the
Selling Key Holder that the Company does not intend to exercise its Right of First Refusal as to
all or a portion of the Capital Stock with respect to any Key Holder Proposed Transfer.

     7.18 “Secondary Refusal Right” means the right, but not the obligation, of Parent to
purchase all or a portion of the Capital Stock proposed to be sold or transferred in a Key Holder
Proposed Transfer (which is not purchased by Company), at the price and on the terms and conditions
specified in the Key Holder Proposed Transfer Notice.

     7.19 “Share Equivalents” means (i) shares of Common Stock, (ii) the number of shares
of Common Stock issuable upon exercise, conversion or exchange of any security that is currently
exercisable for, convertible into or exchangeable for, as of any such date of determination, shares
of Common Stock without payment to the Company of any additional consideration and (iii) the number
of shares of Common Stock issuable upon exercise of any options and/or warrants that are vested and
exercisable as of any such date of determination.

     7.20 “Stockholder Notice” means written notice from a Stockholder notifying Parent
that such Stockholder intends to exercise its Tag-Along Rights as to some or all of his, her or its
Capital Stock with respect to any Parent Proposed Transfer.

     7.21 “Tag-Along Right” means the right, but not the obligation, of a Stockholder to
participate in a Parent Proposed Transfer on the terms and conditions specified in Parent Proposed
Transfer Notice.

21

 

     IN WITNESS WHEREOF, the parties hereto have caused this Right of First Refusal and Co-Sale
Agreement to be duly executed, as of the date first above written.

	 	 	 	 	 
	 	COMVEST NATIONSHEALTH HOLDINGS, LLC

 	 
	 	By:  	/s/
Jose Gordo
 	 
	 	 	Name:  	Jose Gordo 	 
	 	 	Title:  	President 	 
	 
	 	NATIONSHEALTH, INC.

 	 
	 	By:  	/s/
Glenn Parker
 	 
	 	 	Name:  	Glenn Parker 	 
	 	 	Title:  	CEO 	 
	 
	 	GLENN PARKER

 	 
	 	  	/s/ Glenn Parker
 	 
	 	 	 	 
	 	 	 	 
	 
	 	TIMOTHY FAIRBANKS

 	 
	 	  	/s/
Timothy Fairbanks
 	 
	 	 	 	 
	 	 	 	 
	 
	 	LEWIS STONE

 	 
	 	  	/s/
Lewis Stone
 	 
	 	 	 	 
	 	 	 	 
	 
	 	MARK LAMA

 	 
	 	  	/s/
Mark Lama
 	 
	 	 	 	 
	 	 	 	 
	 
	 	RGGPLS, LLC

 	 
	 	By:  	/s/ Glenn Parker
 	 
	 	 	Name:  	Glenn Parker 	 
	 	 	Title:  	CEO 	 

22

 

	 	 	 	 	 

	 	 	 	 	 
	 	MHR CAPITAL PARTNERS MASTER ACCOUNT LP

 	 
	 	By:  	MHR Advisors LLC, its General Partner
 	 
	 	 	 	 
	 	 	 	 
	 
	 	 	 
	 	By:  	
/s/ Hal Goldstein
 	 
	 	 	Name:  	Hal Goldstein 	 
	 	 	Title:  	Authorized Signatory 	 
	 
	 	MHR CAPITAL PARTNERS (100) LP

 	 
	 	By:  	MHR Advisors LLC, its General Partner
 	 
	 	 	 	 
	 	 	 	 
	 
	 	 	 
	 	By:  	                                                 /s/ Hal Goldstein
 	 
	 	 	Name:  	Hal Goldstein 	 
	 	 	Title:  	Authorized Signatory  	 
	 
	 	OTQ LLC

 	 
	 	By:  	/s/ Hal Goldstein
 	 
	 	 	Name:  	Hal Goldstein 	 
	 	 	Title:  	Authorized Signatory 	 
	 
	 	MARK H. RACHESKY, M.D.

(as a record holder and as an authorized signatory

for certain other entities)

 	 
	 	By:  	/s/
Mark H. Rachesky, M.D.
 	 
	 	 	 	 
	 	 	 	 

23EX-4.17

Exhibit 4.17

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE. PLEDGED OR HYPOTHECATED IN
THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE WARRANT UNDER SUCH ACT AND
APPLICABLE LAWS OR SOME OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND
APPLICABLE LAWS OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT
REQUIRED.

			
	 	 	 
	No. WB — 1
	 	Warrant to Purchase 5,126,538 Shares of

Common Stock (subject to adjustment)
	 	 	 
	 
	 	Warrant Issue Date: April 30, 2009

WARRANT TO PURCHASE COMMON STOCK

of

NationsHealth, Inc.

Void after April 30, 2019

     This certifies that, for value received, MHR Capital Partners Master Account LP, an Anguilla, British West Indies limited partnership, or
registered assigns (“Holder”) is entitled, subject to the terms set forth below, to
purchase from NationsHealth, Inc. (the “Company”), a Delaware corporation, 5,126,538 shares
of the Common Stock of the Company, as constituted on the “Warrant Exercisability Date” (as defined
below), upon surrender hereof, at the principal office of the Company referred to below, with the
subscription form attached hereto duly executed, and simultaneous payment therefor in lawful money
of the United States or otherwise as hereinafter provided, at the Exercise Price as set forth in
Section 2 below. The number, character and Exercise Price of such shares of Common Stock are
subject to adjustment as provided below. The term “Warrant” as used herein shall include
this Warrant, which is one of a series of warrants issued for the Common Stock of the Company
(collectively, the “Note Warrants”, and any warrants delivered in substitution or exchange
therefor as provided herein. Capitalized terms used but not otherwise defined herein shall have
the meaning set forth in the Limited Waiver and Consent to the 7 3/4% Convertible Secured Notes,
dated April 30, 2009, by and among the Company, NationsHealth Holdings, L.L.C., a Florida limited
liability company and a wholly-owned subsidiary of the Company, United States Pharmaceutical Group,
L.L.C., a Delaware limited liability company and an indirect wholly-owned subsidiary of the
Company, Diabetes Care & Education, Inc., a South Carolina corporation, National Pharmaceuticals
and Medical Products (USA) LLC, a Florida limited liability company, MHR Capital Partners Master
Account LP (as assignee of MHR Capital Partners (500) LP (f/k/a MHR Capital Partners LP), OTQ LLC,
MHR Capital Partners (100) LP and MHR Capital Partners (500) LP, as collateral agent.

     1. Term of Warrant. Subject to the terms and conditions set forth herein, this
Warrant shall become exercisable, in whole or in part, in the event that (i) the Agreement of
Merger, dated as of April 30, 2009, by and among ComVest NationsHealth Holdings, LLC,

1

 

 NationsHealth
Acquisition Corp. and the Company (the “Merger Agreement”) is terminated, (ii)
the Issuers do not pay all of the outstanding principal and accrued and unpaid interest that
become due under the Bridge Loan on or before the Maturity Date or the applicable due date and
(iii) Parent shall have exercised its option to convert the outstanding obligations under the
Bridge Loan into shares of Series A-1 Preferred Stock pursuant to the terms of the Merger Agreement
(the “Warrant Exercisability Date”), and shall remain exercisable until 5:00 p.m. Eastern
time on the tenth (10th) anniversary of the Warrant Exercisability Date, and shall be
void thereafter; provided however, this Warrant shall be deemed null and void, and of no further
force and effect on the Effective Time (as such term is defined in the Merger Agreement).

     2. Exercise Price. The Exercise Price at which this Warrant may be exercised shall be
$0.05 per share of Common Stock, as adjusted from time to time pursuant to Section 11 hereof.

     3. Exercise of Warrant.

          (a) The purchase rights represented by this Warrant are exercisable by the Holder in whole or
in part, at any time, or from time to time, during the term hereof as described in Section 1 above,
by the surrender of this Warrant and the Notice of Exercise annexed hereto duly completed and
executed on behalf of the Holder, at the office of the Company (or such other office or agency of
the Company as it may designate by notice in writing to the Holder at the address of the Holder
appearing on the books of the Company), upon payment (i) in cash or by check acceptable to the,
Company, (ii) by cancellation by the Holder of indebtedness or other obligations of the Company to
the Holder, or (iii) by a combination of (i) and (ii), of the purchase price of the shares to be
purchased.

          (b) This Warrant shall be deemed to have been exercised immediately prior to the close of
business on the date of its surrender for exercise as provided above, and the person entitled to
receive the shares of Common Stock issuable upon such exercise shall be treated for all purposes as
the holder of record of such shares as of the close of business on such date. As promptly as
practicable on or after such date, and in any event within five (5) days thereafter, the Company
shall, at its expense, issue and deliver to the person or persons entitled to receive the same (i)
a certificate or certificates for the number of shares issuable upon such exercise; (ii) in the
event that this Warrant is exercised in part, a new Warrant of like tenor representing the portion
of the shares of Common Stock, with respect to which this Warrant will not then have been exercised
and exercisable for the number of shares for which this Warrant may then be exercised; and (iii) an
amount in cash in lieu of any fractional shares as provided in Section 4 hereof.

          (c) Net Issue Exercise. Notwithstanding any provisions herein to the contrary, if the
fair market value of one share of Common Stock is greater than the Exercise Price (at the date of
calculation as set forth below), in lieu of exercising this Warrant for cash, the Holder may elect
to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof
being canceled) by surrender of this Warrant at the principal office of the Company together with
the properly endorsed Notice of Exercise and notice of such election in which event the Company
shall issue to the Holder a number of shares of Common Stock computed using the following formula
(and the Holder shall receive the rights and benefits of a record holder of such shares of Common
Stock as described in Section 3(b) hereof):

2

 

	 	 	 	 	 
	X =

	 	Y (A – B)
	 	 
	 

	 	 	 	 
	 

	 	A	 	 

	 	X  = 	 	the number of shares of Common Stock to be issued to the
Holder
	 
	 	Y  = 	 	the number of shares of Common Stock purchasable under the
Warrant or, if only a portion of the Warrant is being exercised, the portion of
the Warrant being canceled (at the date of such calculation)
	 
	 	A  = 	 	the fair market value of one share of the Company’s Common
Stock (at the date of such calculation)
	 
	 	B  = 	 	Exercise Price (as adjusted to the date of such calculation)

For purposes of the above calculation, fair market value of one share of Common Stock shall be
determined by the Company’s Board of Directors in good faith; provided, however, that where there
exists a public market for the Company’s Common Stock at the time of such exercise, the fair market
value per share shall be the average of the closing bid and asked prices of the Common Stock quoted
in the Over-The-Counter Market Summary or the last reported sale price of the Common Stock or the
closing price quoted on the Nasdaq National Market or on any exchange on which the Common Stock is
listed, whichever is applicable, as published in the Western Edition of The Wall Street Journal
over a five (5) day period ending with the third business day before the date of determination of
fair market value. Notwithstanding the foregoing, in the event the Warrant is exercised in
connection with the Company’s initial public offering of Common Stock, the fair market value per
share shall be the per share offering price to the public of the Company’s initial public offering.

          (d) Automatic Exercise. In the event that the Holder does not exercise this Warrant
prior to the tenth anniversary of the Warrant Issue Date, to the extent that this Warrant is then
exercisable and such exercise would result in the issuance of shares of Common Stock to the Holder,
this Warrant shall be deemed automatically exercised for all purposes hereof (including for
purposes of Section 3(b) hereof) through a Net Issue Exercise as described in Section 3(c) hereof
immediately prior to the time at which it would otherwise expire.

          (e) Company to Reaffirm Obligations. The Company will, at the time of each exercise
of this Warrant, upon the request of the Holder, acknowledge in writing its continuing obligation
to afford to the Holder all rights to which such Holder shall continue to be entitled after such
exercise in accordance with the terms of this Warrant, provided that if the Holder shall fail to
make any such request, such failure shall not affect the continuing obligation of the Company to
afford such rights to the Holder.

     4. No Fractional Shares or Scrip. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this Warrant. In lieu of any fractional
share to which the Holder would otherwise be entitled, the Company shall make a cash payment equal
to the Exercise Price multiplied by such fraction.

     5. Replacement of Warrant. On receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate

3

 

issuable upon exercise of this Warrant and, in the case of loss, theft or destruction, on
delivery of an indemnity agreement reasonably satisfactory in form and substance to the Company or,
in the case of mutilation, on surrender and cancellation of this Warrant or stock certificate, the
Company at its expense shall execute and deliver, in lieu of this Warrant or stock certificate, a
new warrant or stock certificate of like tenor and amount.

     6. Rights of Stockholders to Receive Information; Other Investor Rights. So long as
any of the Warrants remain outstanding, the Company shall cause copies of all quarterly and annual
financial reports, information, documents, notices sent or made available by the Company to any of
its stockholders, all regular and periodic reports, registration statements, and prospectuses filed
by the Company with any securities exchanges or with the U.S. Securities and Exchange Commission
(the “SEC”), and other reports (or copies of such portions of any of the foregoing as the
SEC may by rules and regulations prescribe) that the Company is required to file with the SEC
pursuant to Section 13 or 15(d) of the Exchange Act in effect on the Warrant Issue Date (“SEC
Reports”), to be mailed or made available, as the case may be, to the Holders promptly upon
their becoming available and at the request of the Holder. The Company shall make all such
information available to investors, securities analysts and broker dealers who request it in
writing.

          At such time as the Company is not subject to the requirements of Section 13 or Section 15(d)
of the Exchange Act, the Company shall enter into such agreements with the Holders as would provide
the Holders with rights and benefits substantially similar to those provided under Article 4
(Tag-Along) of the Preferred Right of First Refusal and Co-Sale Agreement, entered into as of April
30, 2009, and Article 2 (Preemptive Rights) of the Preferred Stock Investor Rights Agreement,
entered into as of April 30, 2009, as well as annual and monthly financial statements and other
operating reports and information of the Company on such terms and conditions as such information
is provided by the Company to any stockholder.

     7. Transfer of Warrant.

          (a) Warrant Register. The Company will maintain a register (the “Warrant
Register”) containing the names and addresses of the Holder or Holders. Any Holder of this
Warrant or any portion thereof may change his or her address as shown on the Warrant Register by
written notice to the Company requesting such change. Any notice or written communication required
or permitted to be given to the Holder may be delivered or given by mail to such Holder as shown on
the Warrant Register and at the address shown on the Warrant Register. Until this Warrant is
transferred on the Warrant Register of the Company, the Company may treat the Holder as shown on
the Warrant Register as the absolute owner of this Warrant for all purposes, notwithstanding any
notice to the contrary.

          (b) Closing of Books. The Company will at no time close its transfer books in any
manner which interferes with the timely exercise of the rights represented by this Warrant.

          (c) Transferability and Nonnegotiability of Warrant. This Warrant may not be
transferred or assigned in whole or in part without compliance with all applicable federal and
state securities laws by the transferor and the transferee (including the delivery of investment
representation letters and legal opinions reasonably satisfactory to the Company, if such are

4

 

requested by the Company). Subject to the provisions of this Warrant with respect to
compliance with the Securities Act of 1933, as amended (the “Act”), title to this Warrant
may be transferred by endorsement (by the Holder executing the Assignment Form annexed hereto) and
delivery in the same manner as a negotiable instrument transferable by endorsement and delivery.

          (d) Exchange of Warrant Upon a Transfer. On surrender of this Warrant for exchange,
properly endorsed on the Assignment Form and subject to the provisions of this Warrant with respect
to compliance with the Act and with the limitations on assignments and transfers contained in this
Section 7, the Company at its expense shall issue to or on the order of the Holder a new warrant or
warrants of like tenor, in the name of the Holder or as the Holder may direct, for the number of
shares issuable upon exercise hereof.

          (e) Issue Tax. The issuance of certificates for shares of Common Stock upon the total
or partial exercise of this Warrant shall be made without charge to the Holder for any issuance tax
in respect thereof (not including any income or capital tax).

          (f) Compliance with Securities Laws. The Holder of this Warrant, by acceptance hereof
acknowledges that this Warrant and the shares of Common Stock or Common Stock to be issued upon
exercise hereof or conversion thereof are being acquired solely for the Holder’s own account and
not as a nominee for any other party, and for investment, and that the Holder will not offer, sell
or otherwise dispose of this Warrant or any shares of Common Stock or Common Stock to be issued
upon exercise hereof or conversion thereof except under circumstances that will not result in a
violation of the Act or any state securities laws.

     8. Reservation of Stock. The Company covenants that during the term this Warrant is
exercisable, the Company will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of Common Stock upon the exercise of this Warrant and,
from time to time, will take all steps necessary to amend its Certificate of Incorporation (the
“Certificate”) to provide sufficient reserves of shares of Common Stock issuable upon
exercise of the Warrant. The Company further covenants that all shares that may be issued upon the
exercise of rights represented by this Warrant and payment of the Exercise Price, all as set forth
herein, will be free from all liens and charges in respect of the issue thereof (other than taxes
in respect of any transfer occurring contemporaneously or otherwise specified herein) and will not
be subject to any preemptive rights. The Company agrees that its issuance of this Warrant shall
constitute full authority to its officers who are charged with the duty of executing stock
certificates to execute and issue the necessary certificates for shares of Common Stock upon the
exercise of this Warrant.

     9. Notices.

          (a) Whenever the Exercise Price or number of shares purchasable hereunder shall be adjusted
pursuant to Section 11 hereof, the Company shall issue a certificate signed by its Chief Financial
Officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the
adjustment, the method by which such adjustment was calculated, and the Exercise Price and number
of shares purchasable hereunder after giving effect to such adjustment, and shall cause a copy of
such certificate to be mailed (by certified or registered mail, postage prepaid) to the Holder of
this Warrant.

5

 

          (b) In case:

               (i) The Company shall take a record of the holders of its Common Stock (or other stock
or securities at the time receivable upon the exercise of this Warrant) for the purpose of
entitling them to receive any dividend or other distribution, or any right to subscribe for
or purchase any shares of stock of any class or any other securities, or to receive any
other right, or

               (ii) of any capital reorganization of the Company, any reclassification of the capital
stock of the Company, any consolidation or merger of the Company with or into another
corporation, or any conveyance of all or substantially all of the assets of the Company to
another corporation, or

               (iii) of any voluntary dissolution, liquidation or winding-up of the Company,

then, and in each such case, the Company will mail or cause to be mailed to the Holder or Holders a
notice specifying, as the case may be, (A) the date on which a record is to be taken for the
purpose of such dividend, distribution or right, and stating the amount and character of such
dividend, distribution or right, or (B) the date on which such reorganization, reclassification,
consolidation, merger, conveyance, dissolution, liquidation or winding-up is to take place, and the
time, if any is to be fixed, as of which the holders of record-of Common Stock (or such stock or
securities at the time receivable upon the exercise of this Warrant) shall be entitled to exchange
their shares of Common Stock (or such other stock or securities) for securities or other property
deliverable upon such reorganization, reclassification, consolidation, merger, conveyance,
dissolution, liquidation or winding-up. Such notice shall be mailed by certified or registered
mail, postage prepaid at least 15 days prior to the date therein specified.

          (c) All such notices, advices and communications shall be deemed to have been received (i) in
the case of personal delivery, on the date of such delivery and (ii) in the case of mailing, on the
third business day following the date of such mailing.

     10. Amendments.

          (a) Any term of this Warrant may be amended only by an instrument in writing signed by the
Company and the Holder. Any amendment effected in accordance with this Section 10 shall be binding
upon each holder of any of the Warrants, each future Holder of all such Warrants, and the Company.

          (b) No waivers of, or exceptions to, any term, condition or provision of this Warrant, in any
one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of
any such term, condition or provision.

     11. Adjustments. The Exercise Price and the number of shares purchasable hereunder
are subject to adjustment from time to time as follows:

          11.1 Consolidation, Merger, Sale of Assets, etc. If at any time while this Warrant,
or any portion hereof, is outstanding and unexpired, there shall be (i) a reorganization

6

 

(other than a combination, reclassification, exchange or subdivision of shares otherwise
provided for herein), (ii) a merger or consolidation of the Company with or into another
corporation in which the Company is not the surviving entity, or a reverse triangular merger in
which the Company is the surviving entity but the shares of the Company’s capital stock outstanding
immediately prior to the merger are converted by virtue of the merger into other property, whether
in the form of securities, cash, or otherwise, or (iii) a sale or transfer of the Company’s
properties and assets as, or substantially as, an entirety to any other person, then, as a part of
such reorganization, merger, consolidation, sale or transfer, lawful provision shall be made so
that the Holder of this Warrant shall thereafter be entitled to receive upon exercise of this
Warrant, during the period specified herein and upon payment of the Exercise Price then in effect,
the number of shares of stock or other securities or property of the successor corporation
resulting from such reorganization, merger, consolidation, sale or transfer that a holder of the
shares deliverable upon exercise of this Warrant would have been entitled to receive in such
reorganization, consolidation, merger, sale or transfer if this Warrant had been exercised
immediately before such reorganization, merger, consolidation, sale or transfer, all subject to
further adjustment as provided in this Section 11. The foregoing provisions of this Section 11.1
shall similarly apply to successive reorganizations, consolidations, mergers, sales and transfers
and to the stock or securities of any other corporation that are at the time receivable upon the
exercise of this Warrant. If the per-share consideration payable to the Holder hereof for shares
in connection with any such transaction is in a form other than cash or marketable securities, then
the value of such consideration shall be determined in good faith by the Company’s Board of
Directors. In all events, appropriate adjustment (as determined in good faith by the Company’s
Board of Directors) shall be made in the application of the provisions of this Warrant with respect
to the rights and interests of the Holder after the transaction, to the end that the provisions of
this Warrant shall be applicable after that event, as near as reasonably may be, in relation to any
shares or other property deliverable after that event upon exercise of this Warrant. In addition,
if at any time while this Warrant, or any portion hereof, is outstanding and unexpired, (A) there
shall be any transaction (other than the occurrence of conversion of the Bridge Loan as of the
Warrant Exercisability Date) as described in clauses (ii) or (iii) above that constitutes a Sale of
the Company and also constitutes either (x) a Liquidation Event, (y) an Acquisition or (z) an Asset
Transfer (as each such term is defined in the Certificate of Designation for the Series A-1
Preferred Stock) for the Series A-1 Preferred Stock and the Series A-1 Preferred Stock is converted
or redeemed for the Liquidation Amount (as defined in the Certificate of Designation for the Series
A-1 Preferred Stock), and (B) this Warrant has not been exercised prior to the consummation
thereof, this Warrant shall be deemed to be automatically exercised in whole through Net Issue
Exercise as described in Section 3(c) hereof. The Company agrees that such shares to be issued to
the Holder upon Net Issue Exercise as a result of a transaction described in clauses (ii) or (iii)
above shall be deemed to be issued to the Holder as the record owner of such shares as of the close
of business on the date of such transaction.

               A “Sale of the Company” shall mean the sale of the Company to an independent third party or
group of independent third parties pursuant to which such party or parties acquire (a) Capital
Stock (as defined in the Preferred Stock Right of First Refusal and Co-Sale Agreement) of the
Company possessing the voting power under normal circumstances to elect a majority of the Company’s
Board of Directors (whether by merger, consolidation or sale or transfer of the Capital Stock) or
(b) all or substantially all of the Company’s assets determined on a consolidated basis. For
purposes of this definition, “independent third party” means any

7

 

Person who, immediately prior to such contemplated transaction, (w) does not own or have any
voting or economic rights with respect to more than five percent (5%) of the Capital Stock on a
fully-diluted and as converted to Common Stock basis, (x) is not an Affiliate of any Person who
owns or has any voting or economic right with respect to more than five percent (5%) of the Capital
Stock on a fully-diluted and as converted to Common Stock basis, (y) is not Parent, and (z) is not
an Affiliate of Parent.

          11.2 Intentionally Omitted.

          11.3 Reclassification, etc. If the Company, at any time while this Warrant, or any
portion hereof, remains outstanding and unexpired, by reclassification of securities or otherwise,
shall change any of the securities as to which purchase rights under this Warrant exist into the
same or a different number of securities of any other class or classes, this Warrant shall
thereafter represent the right to acquire such number and kind of securities as would have been
issuable as the result of such change with respect to the securities that were subject to the
purchase rights under this Warrant immediately prior to such reclassification or other change and
the Exercise Price therefor shall be appropriately adjusted, all subject to further adjustment as
provided in this Section 11.

          11.4 Split, Subdivision or Combination of Shares. If the Company at any time while
this Warrant, or any portion hereof, remains outstanding and unexpired, shall split, subdivide or
combine the securities as to which purchase rights under this Warrant exist, into a different
number of securities of the same class, the Exercise Price for such securities shall be
proportionately decreased in the case of a split or subdivision or proportionately increased in the
case of a combination.

          11.5 Adjustments for Dividends in Stock or Other Securities or Property. If while
this Warrant, or any portion hereof, remains outstanding and unexpired, the Holders of the
securities as to which purchase rights under this Warrant exist at the time shall have received,
or, on or after the record date fixed for the determination of eligible stockholders, shall have
become entitled to receive, without payment therefor, other or additional stock or other securities
or property of the Company by way of dividend, then and in each case, this Warrant shall represent
the right to acquire, in addition to the number of shares of the security receivable upon exercise
of this Warrant, and without payment of any additional consideration therefor, the amount of such
other or additional stock or other securities or property of the Company that such Holder would
hold on the date of such exercise had it been the holder of record of the security receivable upon
exercise of this Warrant on the date hereof and had thereafter, during the period from the date
hereof to and including the date of such exercise, retained such shares and/or all other additional
stock available by it as aforesaid during such period, giving effect to all adjustments called for
during such period by the provisions of this Section 11.

          11.6 Additional Adjustments. In the event the Company issues any Common Stock or
securities exchangeable or convertible into shares of Common Stock after the Warrant Exercisability
Date, the Exercise Price shall be reduced so that the aggregate number of shares of Common Stock
issued upon exercise of the Note Warrants shall be equal to 10.0% of the issued and outstanding
shares of Common Stock immediately following such issuance (determined on a fully diluted and as
converted to Common Stock basis assuming full conversion or exercise of all

8

 

of the Company’s convertible securities and Options, including the Series A-1 Preferred Stock
issuable under the Bridge Loan and the Note Warrants, and, excluding the Notes).

          11.7 Other Dilutive Events. In case any event shall occur as to which the provisions
of Section 11 are not strictly applicable but failure to make any adjustment would not fairly
protect the purchase rights represented by this Warrant in accordance with the essential intent and
principles of such actions, then, in each such case, the Company shall appoint a firm of
independent certified public accountants of recognized national standing (such firm to be subject
to the approval of the Holder), which shall give their opinion upon the adjustment, if any, on a
basis consistent with the essential intent and principles established in this Section 11, necessary
to preserve, without dilution, the purchase rights represented by this Warrant. Upon receipt of
such opinion, the Company will promptly mail a copy thereof to the Holder and shall make the
adjustments described therein.

          11.8 Treatment of Stock Dividends, Stock Splits, Etc. In case the Company at any time
or from time to time after the date hereof shall declare or pay any dividend on the Common Stock
payable in Common Stock, or shall effect a subdivision of the outstanding shares of Common Stock
into a greater number of shares of Common Stock (by reclassification or otherwise than by payment
of a dividend in Common Stock), then, and in each such case, additional shares of Common Stock
issued pursuant to this Section 11 shall be deemed to have been issued (i) in the case of any such
dividend, immediately after the close of business on the record date for the determination of
holders of any class of securities entitled to receive such dividend, or (ii) in the case of any
such subdivision, at the close of business on the day immediately prior to the day upon which such
corporate action becomes effective.

          11.9 Certificate as to Adjustments; Issuance of New Warrant. Upon the occurrence of
each adjustment or readjustment pursuant to this Section 11, the Company shall, at its expense,
promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to
each Holder of this Warrant (i) a certificate signed by any senior executive of the Company setting
forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or
readjustment is based and (ii) a new Warrant of like tenor representing the number of shares of
Common Stock into which this Warrant is exercisable after giving effect to any and all such
adjustments and readjustments.

          11.10 No Dilution or Impairment. The Company will not, by amendment of its
Certificate or through any consolidation, merger, reorganization, transfer of assets, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the
carrying out of all such terms and in the taking of all such action as may be necessary or
appropriate in order to protect the rights of the Holder of this Warrant against dilution or other
impairment. Without limiting the generality of the foregoing, the Company (a) will not permit the
par value of any shares of stock receivable upon the exercise of this Warrant to exceed the amount
payable therefor upon such exercise, (b) will take all such action as may be necessary or
appropriate in order that the Company may validly and legally issue fully paid and non-assessable
shares of stock on the exercise of the Warrants from time to time outstanding, and (c) will not
take any action which results in any adjustment of the Exercise Price if the total number of shares
of Common Stock issuable after the action upon the exercise of the Warrant would

9

 

exceed the total number of shares of Common Stock then authorized by the Company’s Certificate
and available for the purpose of issue upon such exercise. The Company shall also give written
notice to the Holder at least ten (10) days prior to the date on which any such voluntary action
described in the first sentence of this Section 11.10 shall take place.

     12. Registration Rights and Registration of Common Stock. Upon exercise of this
Warrant, the Holder shall have and be entitled to exercise, together with all other holders of
Registrable Securities possessing registration rights under that certain Registration Rights
Agreement, dated as of February 28, 2005, by and among the Company and the parties who have
executed the counterpart signature pages thereto or are otherwise bound thereby (the
“Registration Rights Agreement”), the rights of registration granted under the Registration
Rights Agreement to Registrable Securities (with respect to the shares of Common Stock issuable
upon exercise of this Warrant). In the event that the Holder provides notice to the Company
requesting that the Company register this Warrant or the shares of Common Stock into which this
Warrant is exercisable, the Company agrees to make such modifications to this Warrant as are
requested by the Holders to facilitate registration, distribution and transfer, of this Warrant
including, among other things, to provide for the appointment of an agent (the “Warrant
Agent”) for the purpose of maintaining the Warrant Register referred to in Section 7(a) hereto,
issuing shares of Common Stock or other securities then issuable upon exercise of this Warrant,
exchanging this Warrant, replacing this Warrant, or any or all of the foregoing. Thereafter, any
such registration, issuance, or replacement, as the case may be, shall be made at the office of the
Warrant Agent. If any shares of Common Stock required to be reserved for purposes of exercise of
this Warrant require registration with or approval of any governmental authority under any federal
or state law (other than the Act) before such shares may be issued upon exercise, the Company will,
at its expense and as expeditiously as possible, use its best efforts to cause such shares to be
duly registered or approved, as the case may be. At any such time as Common Stock is listed on any
national securities exchange, the Company will, at its expense, obtain promptly and maintain the
approval for listing on each such exchange, upon official notice of issuance, the shares of Common
Stock issuable upon exercise of the then outstanding Warrants and maintain the listing of such
shares after their issuance; and the Company will also list on such national securities exchange,
will register under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
and will maintain such listing of, any other securities that at any time are issuable upon exercise
of the Warrants, if and at the time that any securities of the same class shall be listed on such
national securities exchange by the Company.

     13. Legend. The Company covenants that all shares of Common Stock which may be issued
upon exercise of this Warrant will be, upon payment of the Exercise Price and issuance thereof,
fully paid, non-assessable, free of preemptive rights and free from all taxes, liens, charges and
security interests with respect to the issue thereof, provided that until (i) the shares of Common
Stock into which this Warrant may be exercised have been transferred pursuant to Rule 144 under the
Act, (ii) the shares of Common Stock into which this Warrant may be exercised may be transferred
pursuant to Rule 144 under the Act in a single transaction without being subject to any volume or
holding period limitations, or (iii) a registration statement under the Act is effective relating
to the transfer of such shares of Common Stock into which this Warrant may be exercised,
certificates evidencing the shares of Common Stock into which this Warrant may be exercised may
bear the following or a substantially similar legend:

10

 

“THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAW AND MAY NOT BE TRANSFERRED UNLESS (I)
THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE
SECURITIES LAW WITH RESPECT THERETO, (II) PURSUANT TO RULE 144 OF THE SECURITIES ACT OR ANOTHER
EXEMPTION UNDER THE SECURITIES ACT (III) UPON THE ADVICE OF COUNSEL REASONABLY ACCEPTABLE TO THE
ISSUER, REGISTRATION UNDER THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAW IS NOT
REQUIRED IN CONNECTION WITH SUCH TRANSFER”

The Company agrees that the legend set forth above shall be removed and the Company shall issue a
certificate without such legend to the holder of any shares of Common Stock into which this Warrant
may be exercised upon which it is stamped if (a) such shares of Common Stock into which this
Warrant may be exercised may be transferred pursuant to an effective registration statement under
the Securities Act; (b) such holder provides the Company with reasonable assurances that such
shares of Common Stock into which this Warrant may be exercised can be transferred pursuant to Rule
144; or (c) such holder receives advice of counsel reasonably acceptable to the Company to the
effect that a sale or transfer of such shares of Common Stock into which this Warrant may be
exercised may be made without registration under the Securities Act. In the event the above legend
is removed from any shares of Common Stock into which this Warrant may be exercised and thereafter
the effectiveness of a registration statement covering such shares of Common Stock into which this
Warrant may be exercised is suspended or the Company determines that a supplement or amendment
thereto is required by applicable securities laws, then upon reasonable advance written notice to
the holders of shares of Common Stock into which this Warrant may be exercised, the Company may
require that the above legend be placed on any such shares of Common Stock into which this Warrant
may be exercised that cannot then be sold pursuant to an effective registration statement or
pursuant to Rule 144 and the holders thereof shall cooperate in the replacement of such legend.
Such legend shall thereafter be removed when such shares of Common Stock into which this Warrant
may be exercised may again be transferred pursuant to an effective registration statement or
pursuant to Rule 144.

     14. Intentionally Omitted.

     15. Remedies. In case any one or more of the covenants and agreements contained in
this Warrant is breached, the Holder may proceed to protect and enforce their or its rights either
by suit in equity and/or by action at law, including, but not limited to, an action for damages as
a result of any such breach and/or an action for specific performance of any such covenant or
agreement contained in this Warrant.

     16. Severability. The invalidity or unenforceability of any provision of this Warrant
in any jurisdiction will not affect the validity or enforceability of such provision in any other
jurisdiction, or affect any other provision of this Warrant, which will remain in full force and
effect.

11

 

     17. Successors and Assigns. The provisions of this Warrant shall be binding upon
and inure to the benefit of the parties hereto and their respective successors, assigns and
transferees.

     18. Further Assurances. The Company agrees that it will execute and record such
documents as the Holder shall reasonably request to secure for the Holder any of the rights
represented by this Warrant.

     19. Descriptive Headings and Governing Law. The description headings of the several
sections and paragraphs of this Warrant are inserted for convenience only and do not constitute a
part of this Warrant. This Warrant shall be construed and enforced in accordance with, and the
rights of the parties shall be governed by, the laws of the State of New York without regard to
conflicts of law provisions.

12

 

     IN WITNESS WHEREOF, NationsHealth, Inc. has caused this Warrant to be executed by its officers
thereunto duly authorized by its board of directors, and the undersigned has accepted this Warrant
and the terms and conditions hereof by their execution in the space provided below.

Dated: April 30, 2009

 

	 	 	 	 	 
	HOLDER:

MHR CAPITAL PARTNERS MASTER ACCOUNT LP

 	 
	By:  	MHR Advisors LLC, its General Partner
 	 
	 	 	 
	 
	 	 
	By:  	/s/ Hal Goldstein
 	 
	 	Name:  	Hal Goldstein 	 
	 	Title:  	Vice President 	 
	 

	 	 	 	 	 
	NationsHealth, Inc.

 	 
	By:  	/s/ Glenn Parker
 	 
	 	Glenn Parker 	 
	 	CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]